Impact of p53-associated acute myeloid leukemia hallmarks on metabolism and the immune environment
M Chomczyk, L Gazzola, S Dash, P Firmanty… - Frontiers in …, 2024 - frontiersin.org
Acute myeloid leukemia (AML), an aggressive malignancy of hematopoietic stem cells, is
characterized by the blockade of cell differentiation, uncontrolled proliferation, and cell …
characterized by the blockade of cell differentiation, uncontrolled proliferation, and cell …
The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment
S Zheng, Y Tong, L Yang, J Chen, Y Tan - Annals of Hematology, 2024 - Springer
Acute myeloid leukemia (AML) is the most prevalent hematologic malignancy in adults. In
2022, the European LeukemiaNet (ELN) has updated its prognostic system that incorporates …
2022, the European LeukemiaNet (ELN) has updated its prognostic system that incorporates …
[HTML][HTML] Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial
MY Konopleva, M Dail, NG Daver, JS Garcia… - … Myeloma and Leukemia, 2024 - Elsevier
Background Therapies for relapsed/refractory acute myeloid leukemia remain limited and
outcomes poor, especially amongst patients who are ineligible for cytotoxic chemotherapy or …
outcomes poor, especially amongst patients who are ineligible for cytotoxic chemotherapy or …
Combinations of RAS pathway inhibitors with targeted agents are active in spheroids of patient-derived cells with oncogenic KRAS variants from multiple cancer types
Z Davoudi, TS Dexheimer, NP Coussens, T Silvers… - bioRxiv, 2024 - biorxiv.org
The KRAS gene is among the most frequently altered genes in cancer and the KRAS protein
was long deemed undruggable. Recent strategies to target oncogenic KRAS have included …
was long deemed undruggable. Recent strategies to target oncogenic KRAS have included …